The Sabin Vaccine Institute has expanded its clinical trial for an investigational Marburg virus vaccine in Rwanda, increasing the number of participants to include mine workers at risk of exposure. The expanded trial aims to assess the vaccine’s safety, immunogenicity, and efficacy. This initiative comes amidst a large-scale Marburg outbreak in Rwanda, where over 1,500 frontline workers have already been vaccinated with the Sabin vaccine.